CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected in ...
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the ...
The Food and Drug Administration has approved two new ways to use a higher-dose, longer-acting version of Regeneron Pharmaceuticals’ Eylea, positioning the medicine to better compete in the eye ...
Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has extended the target action dates for Eylea HD (aflibercept) injection 8 mg regulatory submissions. Eylea HD is the higher dose of ...
Since Roche gained approval for its eye disease medication Vabysmo in 2022, it has stormed a market dominated by Regeneron and Bayer’s Eylea. Friday, Roche took another step in its advancement of the ...
(Reuters) - Regeneron Pharmaceuticals Inc said on Thursday the U.S. Food and Drug Administration declined to approve a pre-filled syringe version of its blockbuster eye drug Eylea, and has sought ...
Here’s a little business drama to go with your morning coffee. Remember Regeneron Pharmaceuticals, developer of drugs to treat eye diseases, allergic and inflammatory conditions, cancer, heart issues, ...
Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected second-quarter results despite lower sales from its lead drug Eylea. The stock rose 1.3% following the results but was trading lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback